Targeting cancer with power and precision


Eleven Biotherapeutics, Inc. (NASDQ: EBIO) is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on the company's targeted protein therapeutics (TPTs) platform. The company believes its TPTs can potentially offer significant advantages in treating cancer versus existing antibody drug conjugate technologies. Eleven’s approach to drug design creates TPTs that it believes facilitate effective tumor targeting with cancer cell-killing properties unique to protein payloads versus small molecules. The ability of TPTs cancer cell-killing properties to promote an anti-tumor immune response suggest that TPTs will potentially combine well with immune oncology drugs.

 

In September of 2016, Eleven announced the acquisition of Viventia Bio Inc. Eleven’s pipeline now includes Viventia’s lead product candidates Vicinium and Proxinium.

 


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.elevenbio.com

Recent News

April 2, 2017
Eleven Biotherapeutics Presents New Preclinical Data at AACR Supporting the Potential of the Company's Locally- and Systematically-Administered Drug Candidates

March 27, 2017
Eleven Biotherapeutics to Present New Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

March 24, 2017
Eleven Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

Read More News

Associated Team Members

Mark Levin
Partner

Cary Pfeffer, M.D.
Partner

Abbie Celniker, Ph.D.
Partner